KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Change in Cash (2019 - 2025)

GoodRx Holdings' Change in Cash history spans 7 years, with the latest figure at -$7.8 million for Q3 2025.

  • For Q3 2025, Change in Cash rose 92.3% year-over-year to -$7.8 million; the TTM value through Sep 2025 reached -$150.2 million, up 59.52%, while the annual FY2024 figure was -$224.0 million, 163.88% down from the prior year.
  • Change in Cash for Q3 2025 was -$7.8 million at GoodRx Holdings, up from -$19.7 million in the prior quarter.
  • Across five years, Change in Cash topped out at $32.9 million in Q3 2023 and bottomed at -$147.4 million in Q1 2025.
  • The 5-year median for Change in Cash is -$7.8 million (2025), against an average of -$36.7 million.
  • The largest annual shift saw Change in Cash surged 1976.68% in 2023 before it tumbled 3655.01% in 2024.
  • A 5-year view of Change in Cash shows it stood at $29.1 million in 2021, then fell by 2.43% to $28.4 million in 2022, then crashed by 532.04% to -$122.6 million in 2023, then soared by 120.04% to $24.6 million in 2024, then plummeted by 131.7% to -$7.8 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Change in Cash are -$7.8 million (Q3 2025), -$19.7 million (Q2 2025), and -$147.4 million (Q1 2025).